Hypertension screening tools: a literature review

In the Russian Federation, hypertension (HTN) remains a socially significant disease with a high burden on the healthcare system causing significant socioeconomic losses. Currently, the most common and standard method of screening for HTN is direct blood pressure measurement in a healthcare facility. However, population coverage remains incomplete, primarily due to low preventive activity in certain age groups, particularly young people and individuals of working age. The high prevalence of HTN and its consequences necessitate the development of non-invasive population-based screening tools aimed at the early detection of HTN risk factors or the underlying disease among different age groups. A questionnaire may be the most accessible and simple population-based screening tool. This review analyzes and summarizes the experience of using questionnaires as a screening tool for HTN in various countries. Based on the review results, a model for population-based screening for HTN and its risk factors outside of healthcare facilities is proposed.

1. Chen S, Sudharsanan N, Huang F, et al. Impact of community based screening for hypertension on blood pressure after two years: regression discontinuity analysis in a national cohort of older adults in China. BMJ. 2019;366:l4064. doi:10.1136/bmj.l4064.

2. Balanova YuA, Drapkina OM, Kutsenko VA, et al. Hypertension in the Russian population during the COVID-19 pandemic: sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Cardiovascular Therapy and Prevention. 2023;22(8S):3785. (In Russ.) doi:10.15829/1728-8800-2023-3785. EDN: YRUNUX.

3. Drapkina OM, Kontsevaya AV, Deev IA. Programmatic approach to the prevention and control of hypertension as a key reserve for reducing mortality in the Russian Federation. Cardiovascular Therapy and Prevention. 2025;24(12):4698. (In Russ.) doi:10.15829/1728-8800-2025-4698. EDN: KRABNJ.

4. Rahman M, Zaman MM, Islam JY, et al. Prevalence, treatment patterns, and risk factors of hypertension and pre-hypertension among Bangladeshi adults. J Hum Hypertens. 2018;32(5):334-48. doi:10.1038/s41371-017-0018-x.

5. Mamdouh H, Alnakhi WK, Hussain HY, et al. Prevalence and associated risk factors of hypertension and pre-hypertension among the adult population: findings from the Dubai Household Survey, 2019. BMC Cardiovasc Disord. 2022;22(1):18. doi:10.1186/s12872-022-02457-4.

6. Reddy SP, Mbewu AD, Williams DR, et al. Race, geographical location and other risk factors for hypertension: South African National Health and Nutrition Examination Survey 2011/12. SSM. Popul Health. 2021;16:100986. doi:10.1016/j.ssmph.2021.100986.

7. Dereje N, Earsido A, Temam L, et al. Uncovering the high burden of hypertension and its predictors among adult population in Hosanna town, southern Ethiopia: a community-­based cross-­sectional study. BMJ Open. 2020;10(10):e035823. doi:10.1136/bmjopen-2019-035823.

8. Dhungana RR, Pedisic Z, Dhimal M, et al. Hypertension screening, awareness, treatment, and control: a study of their prevalence and associated factors in a nationally representative sample from Nepal. Glob Health Action. 2022;15(1):2000092. doi:10.1080/16549716.2021.2000092.

9. Amadi CE, Ale OK, Okorafor UC, et al. Unmasking the contem­porary burden of hypertension in Lagos, Nigeria: insights from an opportunistic screening. BMC Public Health. 2026;26(1):634. doi:10.1186/s12889-026-26310-x.

10. Beaney T, Kerr GK, Kiru G, et al. May Measurement Month 2022: results from the global blood pressure screening campaign. BMJ Glob Health. 2024;9(12):e016557. doi:10.1136/bmjgh-2024-016557.

11. Tripathy JP, Thakur JS, Jeet G, et al. Alarmingly high prevalence of hypertension and pre-hypertension in North India-results from a large cross-­sectional STEPS survey. PloS One. 2017;12(12):e0188619. doi:10.1371/journal.pone.0188619.

12. Peltzer K, Pengpid S. The prevalence and social determinants of hypertension among adults in Indonesia: A cross‐sectio­nal population‐based national survey. Int J Hypertens. 2018;1: 5610725. doi:10.1155/2018/5610725.

13. Mathur P, Kulothungan V, Leburu S, et al. National noncom­mu­nicable disease monitoring survey (NNMS) in India: Estima­ting risk factor prevalence in adult population. PloS One. 2021;16(3): e0246712. doi:10.1371/journal.pone.0246712.

14. Calas L, Subiros M, Ruello M, et al. Hypertension prevalence, awareness, treatment and control in 2019 in the adult population of Mayotte. Eur J Public Health. 2022;32(3):408-14. doi:10.1093/eurpub/ckac015.

15. Abdul-­Razak S, Daher AM, Ramli AS, et al. Prevalence, aware­ness, treatment, control and socio demographic determinants of hypertension in Malaysian adults. BMC Public Health. 2016;16(1): 351. doi:10.1186/s12889-016-3008-y.

16. Rohla M, Haberfeld H, Sinzinger H, et al. Systematic screening for cardiovascular risk at pharmacies. Open Heart. 2016;3(2): e000497. doi:10.1136/openhrt-2016-000497.

17. Pantell MS, Prather AA, Downing JM, et al. Association of social and behavioral risk factors with earlier onset of adult hypertension and diabetes. JAMA Netw Open. 2019;2(5):e193933. doi:10.1001/jamanetworkopen.2019.3933.

18. Lopez-­Neyman SM, Davis K, Zohoori N, et al. Racial disparities and prevalence of cardiovascular disease risk factors, cardio­metabolic risk factors, and cardiovascular health metrics among US adults: NHANES 2011-2018. Sci Rep. 2022;12(1):19475. doi:10.1038/s41598-022-21878-x.

19. Mohamed SF, Mutua MK, Wamai R, et al. Prevalence, awareness, treatment and control of hypertension and their determinants: results from a national survey in Kenya. BMC Public Health. 2018;18(3):1219. doi:10.1186/s12889-018-6052-y.

20. Du M, Yin S, Wang P, et al. Self-reported hypertension in Northern China: a cross-­sectional study of a risk prediction model and age trends. BMC Health Serv Res. 2018;18(1):475. doi:10.1186/s12913-018-3279-3.

21. Li Z, Cao L, Zhou Z, et al. Factors influencing the progression from prehypertension to hypertension among Chinese middle-aged and older adults: a 2-year longitudinal study. BMC Public Health. 2023;23(1):339. doi:10.1186/s12889-022-14410-3.

22. Montagna S, Pengo MF, Ferretti S, et al. Machine learning in hypertension detection: A study on world hypertension day data. J Med Syst. 2022;47(1):1. doi:10.1007/s10916-022-01900-5.

23. Huang W, Ying TW, Chin, WLC, et al. Application of ensemble machine learning algorithms on lifestyle factors and wearables for cardiovascular risk prediction. Sci Rep. 2022;12(1):1033. doi:10.1038/s41598-021-04649-y.

24. Adeneyi OA. Prevalence, Awareness and Correlates of Hyper­ten­sion Among Urban Public Workers in Ondo State, Nigeria. Online J Health Allied Sci. 2017;16(3):1.

25. Agbaza-­Mogbojuri B. Lifestyle, stress, and treatment adherence as predictors of hypertension risk: A longitudinal public health study. WJBPHS. 2023;16(1):273-281. doi:10.30574/wjbphs.2023.16.1.0444.

26. Rotar OP, Ilyanova IN, Boyarinova MA, et al. 2023 All-­Rus­sian screening for hypertension: results. Russian Journal of Cardio­logy. 2024;29(5):5931. (In Russ) doi:10.15829/1560-4071-2024-5931.

27. Islam SMS, Talukder A, Awal MA, et al. Machine learning approaches for predicting hypertension and its associated factors using population-­level data from three South Asian count­ries. Front Cardiovasc Med. 2022;9:839379. doi:10.3389/fcvm.2022.839379.

28. Sathish T, Kannan S, Sarma PS, et al. A risk score to predict hypertension in primary care settings in rural India. Asia-­Pac J Public Health. 2016;28(1 Suppl):26S-31S. doi:10.1177/1010539515604701.

29. Abrarov RA. Prediction of risk of arterial hypertension among female adolescents born preterm. Kazan Medical Journal. 2018; 99(4):580-5. (In Russ.) doi:10.17816/KMJ2018-580.

30. Mahmoud I, Sulaiman N, Hussein A, et al. A hypertension risk score for adults: a population-­based cross-­sectional study from the Dubai Household Survey 2019. Epidemiol Health. 2021;43: e2021064. doi:10.4178/epih.e2021064.

31. Kanellakis S, Mavrogianni C, Karatzi K, et al. Development and va­lidation of two self-reported tools for insulin resistance and hy­per­tension risk assessment in a European cohort: the Feel4Diabetes-­study. Nutrients. 2020;12(4):960. doi:10.3390/nu12040960.

32. Oishi E, Hata J, Honda T, et al. Development of a risk prediction model for incident hypertension in Japanese individuals: the Hisayama Study. Hypertens Res. 2021;44(9):1221-9. doi:10.1038/s41440-021-00673-7.

33. Chowdhury MZI, Leung AA, Sikdar KC, et al. Development and validation of a hypertension risk prediction model and construction of a risk score in a Canadian population. Sci Rep. 2022;12(1):12780. doi:10.1038/s41598-022-16904-x.

34. Kawasoe M, Kawasoe S, Kubozono T, et al. Development of a risk prediction score for hypertension incidence using Japanese health checkup data. Hypertens Res. 2022;45(4):730-40. doi:10.1038/s41440-021-00831-x.

35. Zhao H, Zhang X, Xu Y, et al. Predicting the risk of hypertension based on several easy-to-collect risk factors: a machine learning method. Front Public Health. 2021;9:619429. doi:10.3389/fpubh.2021.619429.

36. Kurniawan R, Utomo B, Siregar KN, et al. Hypertension prediction using machine learning algorithm among Indonesian adults. IAES Int J Artif Intell. 2023;12(2):776. doi:10.11591/ijai.v12.i2.pp776-784.

37. Ji W, Zhang Y, Cheng Y, et al. Development and validation of prediction models for hypertension risks: A cross-­sectional study based on 4,287,407 participants. Front Cardiovasc Med. 2022;9:928948. doi:10.3389/fcvm.2022.928948.

38. Nguyen TPL, Wright EP, Nguyen TT, et al. Cost-effectiveness analysis of screening for and managing identified hypertension for cardiovascular disease prevention in Vietnam. PloS One. 2016;11(5):e0155699. doi:10.1371/journal.pone.0155699.

39. Kaur G, Chauhan AS, Prinja S, et al. Cost-effectiveness of population-­based screening for diabetes and hypertension in India: an economic modelling study. Lancet Public Health. 2022;7(1):e65-73. doi:10.1016/S2468-2667(21)00199-7.

40. Neupane D, McLachlan CS, Mishra SR, et al. Effectiveness of a lifestyle intervention led by female community health volunteers versus usual care in blood pressure reduction (COBIN): an open-label, cluster-­randomised trial. Lancet Glob Health. 2018;6(1):e66-73. doi:10.1016/S2214-109X(17)30411-4.